Study guide

2.3 Harm Reduction, Overdose Prevention, and Low-Threshold Engagement

National Certified Addiction Counselor NCAC

Track your progress as you read

Finished sections get a check mark.

1 Introduction to NCAC & Addiction Counseling

0.1 NCAC Exam Structure, Eligibility, and Scoring 0.2 The 12 Core Functions & TAP 21 Addiction Counseling Competencies 0.3 Study Strategy and Exam Navigation for Addiction Counselors

2 Chapter 1: Screening, Intake, and Initial Orientation

1.1 Screening Instruments, Risk Stratification, and SBIRT Protocols 1.2 The Intake Process: Clinical and Administrative Data Collection 1.3 Client Orientation, Rights, Informed Consent, and Program Expectations 1.4 Mandated, Court-Referred, and Justice-Involved Clients

3 Chapter 2: Initial Case Management and Referral Foundations

2.1 Stages of Change (Transtheoretical Model) and Initial Engagement 2.2 Referral Coordination, Community Resources, and Interdisciplinary Linkage 2.3 Harm Reduction, Overdose Prevention, and Low-Threshold Engagement

4 Chapter 3: Biopsychosocial Assessment & Diagnostic Foundations

3.1 Comprehensive Biopsychosocial Assessment & The Addiction Severity Index (ASI) 3.2 DSM-5-TR Substance Use Disorders: Criteria, Specifiers, and Neurobiology of Addiction 3.3 Behavioral and Process Addictions: Assessment and Clinical Features 3.4 Models and Theories of Addiction Etiology

5 Chapter 4: Co-Occurring Disorders & Risk Assessment

4.1 Co-Occurring Mental Health Disorders & Differential Diagnosis 4.2 Suicide Risk Assessment, Self-Harm, and Crisis Safety Planning 4.3 Trauma-Informed Assessment, PTSD, and Adverse Childhood Experiences (ACEs)

6 Chapter 5: Medical, Toxicology, and Special Population Considerations

5.1 Medical Evaluation, Toxicology Screening, and Infectious Disease Risks 5.2 Cultural, Developmental, and Special Population Assessment Adaptations 5.3 Psychopharmacology of the Major Drug Classes 5.4 Physiological Effects of Substance Use Across Body Systems

7 Chapter 6: The ASAM Criteria & Level of Care Placement

6.1 The ASAM Criteria: The Six Multidimensional Assessment Dimensions 6.2 ASAM Continuum of Care: Levels 0.5 Through 4.0 6.3 Placement Matching, Continued Service, Transfer, and Discharge Criteria

8 Chapter 7: Individualized Treatment Planning & Pharmacotherapy

7.1 Developing Measurable, Individualized Treatment Plans (SMART Objectives) 7.2 Medications for Addiction Treatment (MAT/MOUD) and Pharmacotherapies 7.3 Monitoring Clinical Progress, Plan Review, and Interdisciplinary Care

9 Chapter 8: Case Management, Relapse Prevention & Continuing Care

8.1 Case Management Models, Advocacy, and Resource Coordination 8.2 Relapse Dynamics, Warning Signs, and Relapse Prevention Models 8.3 Continuing Care, Recovery Capital, and Peer Support Systems 8.4 Clinical Documentation, Progress Notes, and the Golden Thread 8.5 Outcome Measurement, Program Evaluation, and Evidence-Based Practice

10 Chapter 9: Core Counseling Modalities & Individual Skills

9.1 Motivational Interviewing: Spirit, Principles, OARS, and Change Talk 9.2 Cognitive Behavioral Therapy (CBT) & REBT in Addiction Treatment 9.3 Additional Evidence-Based Approaches: SFBT, Contingency Management, and Mindfulness 9.4 Mutual-Help Programs, Twelve-Step Facilitation, and Recovery Support

11 Chapter 10: Group Dynamics & Family Systems

10.1 Group Counseling Dynamics, Types of Groups, and Yalom's Therapeutic Factors 10.2 Group Leadership Skills, Managing Challenging Behaviors, and Developmental Stages 10.3 Family Systems Theory, Roles, Codependency, and Family Interventions

12 Chapter 11: Crisis Intervention & Psychoeducation

11.1 Crisis Intervention Models, De-escalation Techniques, and Overdose Response 11.2 Psychoeducation, Health Literacy, and Client Self-Advocacy

13 Chapter 12: Legal Standards, Confidentiality & 42 CFR Part 2

12.1 Federal Confidentiality Regulations: 42 CFR Part 2 and HIPAA Integration 12.2 Duty to Warn / Protect (Tarasoff) and Mandated Reporting Laws 12.3 Legal Issues, Subpoenas, Court Mandates, and Clinical Record Retention 12.4 Confidentiality with Minors, Groups, Families, and Collaterals

14 Chapter 13: NAADAC Ethics, Cultural Humility & Supervision

13.1 The NAADAC Code of Ethics: Core Principles, Boundaries, and Dual Relationships 13.2 Cultural Humility, Implicit Bias, and Culturally Responsive Care 13.3 Clinical Supervision, Professional Impairment, Compassion Fatigue, and Self-Care 13.4 Technology in Practice: Telehealth, E-Supervision, AI, and Social Media 13.5 Professional Development, Credentialing, and Scope of Practice

2.3 Harm Reduction, Overdose Prevention, and Low-Threshold Engagement

Key Takeaways Explain This Topic AI

Harm reduction is a set of practices and a stance that meets people where they are, reduces the harms of drug use without requiring abstinence as a precondition for services, and is compatible with abstinence-oriented treatment rather than opposed to it.

Naloxone reverses opioid overdose by competitively displacing opioids at the mu receptor; a 4 mg naloxone nasal spray has been available over the counter in the United States since 2023, and every client and family member should leave treatment with a kit and training.

Naloxone does not reverse xylazine, a veterinary sedative increasingly present in the illicit opioid supply, but naloxone is still administered because opioids are usually present too; xylazine also causes severe soft-tissue wounds requiring medical referral.

Syringe services programs are associated with people who inject drugs being substantially more likely to enter treatment and to stop injecting, and are not associated with increases in crime or drug use in the surrounding community.

Overdose risk spikes after any period of reduced tolerance, including release from jail, discharge from residential treatment, and discontinuation of extended-release naltrexone, so tolerance-loss counseling is a required element of every discharge plan.

Last updated: August 2026

2.3 Harm Reduction, Overdose Prevention, and Low-Threshold Engagement

Harm reduction is both a set of specific practices and a stance toward people who use drugs. The practices are concrete: naloxone distribution, sterile syringe access, drug checking, safer-use education, wound care, low-threshold medication access. The stance is that a person's life and health have value right now, whether or not they stop using today , and that services should not be withheld as leverage to force a decision the person has not yet made.

For the addiction counselor, the critical point is that harm reduction and abstinence-oriented treatment are not competitors. A counselor can hold abstinence as a clinical goal, work actively toward it, and still make sure the client has naloxone in their pocket tonight. The alternative — withholding overdose prevention until someone commits to abstinence — is a strategy that only works on people who survive.

1. The Harm Reduction Stance in Clinical Practice

Principle What It Looks Like in the Session What It Is Not

Meet the person where they are Working on the goal the client actually has — reducing injection frequency, avoiding using alone — while keeping the door open to more Agreeing that nothing needs to change

Any positive change counts Documenting reduced use, safer route of administration, or reengagement with medical care as legitimate treatment progress Abandoning measurable objectives

Reduce harm, not only use Addressing overdose risk, infection, wounds, housing, and violence as clinical targets in their own right Ignoring the substance use disorder

Non-coercive and non-judgmental Continuing to serve a client who returns to use; no discharge-for-relapse policy Failing to reassess the level of care when risk rises

People who use drugs lead Involving people with lived experience in service design; respecting the client's expertise about their own use Deferring clinical judgment on medical risk

Important

Administrative discharge for relapse is a clinical failure, not a consequence. Discharging a client from addiction treatment for exhibiting the primary symptom of the disorder being treated is now widely regarded as contraindicated. When use continues, the correct response is a reassessment of the ASAM dimensional profile and a revised treatment plan — which may well mean a more intensive level of care — not termination. See Section 6.3 on continued service and transfer criteria.

  • 2. Opioid Overdose: Recognition and Response
  • Recognizing an overdose

The classic opioid overdose triad is pinpoint pupils, respiratory depression, and depressed level of consciousness . In practice, the counselor is looking for: unresponsive to sternal rub or shouting; breathing that is slow, shallow, gurgling, or absent; blue or grey lips and fingertips (cyanosis); limp body; and slow or absent pulse.

Distinguish overdose from heavy intoxication: a person who is very high but responsive to a sternal rub and breathing normally is not in an overdose. When in doubt, treat it as an overdose — naloxone given to a person who has not taken opioids causes no harm .

Naloxone

Mechanism. Naloxone is a competitive mu-opioid receptor antagonist with a higher receptor affinity than most opioid agonists. It displaces the opioid, restoring respiratory drive within two to three minutes when given intranasally or intramuscularly.

Forms. The 4 mg naloxone nasal spray has been available over the counter in the United States since 2023 , which means clients and family members can buy it without a prescription. Higher-dose nasal formulations, intramuscular and subcutaneous injection (0.4 to 2 mg), and a nalmefene nasal spray are also available. Many states also have standing orders and free distribution through health departments and syringe services programs.

The half-life problem. Naloxone's duration of action is roughly 30 to 90 minutes , which is shorter than the duration of many opioids — notably methadone, and fentanyl in body compartments after heavy exposure. A person can be reversed, then re-overdose as the naloxone wears off . This is why calling 911 and staying with the person are not optional add-ons, and why repeat dosing may be required.

Post-reversal experience. Reversal precipitates acute withdrawal — nausea, vomiting, agitation, severe craving. The person may be angry at being "wasted." Counsel families in advance: this reaction is expected, it is not ingratitude, and the person is at very high risk of using again immediately to relieve withdrawal, which is itself a re-overdose risk.

Overdose response sequence

Check responsiveness — shout, sternal rub.

Call 911. Most states have Good Samaritan laws providing some protection from drug-possession charges for those who call; the protections vary by state, so know yours.

Give naloxone — one dose intranasally, repeat every two to three minutes if there is no response.

Support breathing — rescue breaths if trained; chest compressions if there is no pulse.

Recovery position to prevent aspiration if breathing resumes and you must step away.

Stay until emergency services arrive; monitor for re-sedation.

3. The Contaminated Supply: Fentanyl and Xylazine

Fentanyl now dominates the illicit opioid supply in most of the United States and is also pressed into counterfeit pills sold as oxycodone, alprazolam, or stimulants. Its potency and rapid onset compress the window for intervention and make dose estimation impossible for the user. Fentanyl test strips allow a person to check a sample before use; they detect fentanyl but not quantity, and a negative strip does not make a supply safe.

Xylazine ("tranq") is a veterinary alpha-2 agonist sedative that is not an opioid and has been found widely in the illicit opioid supply. Three clinical facts matter:

Naloxone does not reverse xylazine. Give naloxone anyway — opioids are almost always present as well, and reversing the opioid component restores respiratory drive.

Sedation may persist after naloxone because the xylazine component is untouched. Continue rescue breathing and emergency response rather than concluding the naloxone "did not work."

Xylazine causes severe necrotic soft-tissue wounds , often at sites distant from injection. Wound assessment and prompt medical referral belong in routine counseling contact; untreated wounds progress to amputation.

Safer-use counseling points that reduce fatality risk without requiring abstinence: never use alone (or use a virtual overdose-response hotline); stagger use with others so one person can respond; start with a smaller test dose after any break; avoid mixing opioids with alcohol or benzodiazepines; keep naloxone within arm's reach.

4. Syringe Services and Infectious Disease Prevention

Syringe services programs (SSPs) provide sterile injection equipment, safe disposal, naloxone, testing, wound care, and — critically — a relationship with a person who is not asking them to quit today . The evidence base is consistent: participation is associated with substantially higher rates of entering treatment and of stopping injection, and with reduced HIV and hepatitis C transmission, while community-level fears about increased crime or drug use have not been borne out.

For the counselor, the practical work is referral and normalization : knowing where the nearest SSP is, being able to describe what happens there, and not treating a client's SSP participation as ambivalence about recovery. Infection control, HIV and HCV screening, and universal precautions are covered in Section 5.1.

5. The Tolerance-Loss Windows

The most predictable overdose deaths in addiction treatment occur when tolerance has fallen and the person returns to a previously routine dose. Every one of these transitions requires explicit counseling and a naloxone kit:

Window Why Risk Spikes Required Counselor Action

Release from jail or prison Weeks or months of enforced abstinence with no tolerance Naloxone at release, same-week appointment, MOUD continuity arranged before release

Discharge from residential or withdrawal management Tolerance lost during the stay; discharge is a high-risk day Naloxone in hand at discharge, warm handoff to the next level of care, explicit "your old dose can kill you" conversation

Discontinuing extended-release naltrexone Receptor upregulation and lost tolerance while blocked Plan the transition, discuss the elevated risk, offer alternative MOUD

After any period of reduced use Hospitalization, illness, a period of abstinence between episodes Repeat tolerance-loss counseling every time

Return to use after a lapse Person often uses their pre-treatment amount Include the tolerance-loss script in every relapse prevention plan (Section 8.2)

Important

The single sentence to say out loud. "If you use again after this, your tolerance is not what it was — the amount that used to be normal for you can kill you now. Use less, don't use alone, and keep this naloxone where someone can reach it." Document that you said it.